期刊
DRUG DESIGN DEVELOPMENT AND THERAPY
卷 10, 期 -, 页码 3933-3946出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S116286
关键词
6-mercaptopurine; cisplatin; mesoporous silica nanoparticles; cancer therapy; nanomedicine
资金
- Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, PHR (IHLB) [TJSHG201310025008]
- NSFC [21171120, 81172930, 81270046, 81373265]
- Beijing Natural Science Foundation [7132020, 7132032]
- Beijing Nova Programme [xx2013039]
- 863 programme [2015AA020902]
- Project for Science and Technology Development, Beijing Commission of Education [SQKM201210025007]
- Project of Construction of Innovative Teams and Teacher Career Development for Universities and Colleges Under Beijing Municipality
In the treatment of cancer patients, cisplatin (CDDP) exhibits serious cardiac and renal toxicities, while classical combinations related to CDDP are unable to solve these problems and may result in worse prognosis. Alternately, this study covalently conjugated 6-mercaptopurine (6MP) onto the surface of mercapto-modified mesoporous silica nanoparticles (MSNS) to form MSNS-6MP and loaded CDDP into the holes on the surface of MSNS-6MP to form MSNS-6MP/CDDP, a tumor-targeting nano-releasing regime for CDDP and 6MP specifically. In the S180 mouse model, the anti-tumor activity and overall survival of MSNS6MP/CDDP (50 mg.kg(-1).day(-1), corresponding to 1 mg.kg(-1).day(-1) of 6MP and 5 mg.kg(-1).day(-1) of CDDP) were significantly higher than those of CDDP alone (5 mg.kg(-1).day(-1)) or CDDP (5 mg.kg(-1).day(-1)) plus 6MP (1 mg.kg(-1).day(-1)). The assays of serum alanine aminotransferase, aspartate aminotransferase and creatinine, as well as the images of myocardium and kidney histology, support that MSNS-6MP/CDDP is able to completely eliminate liver, kidney and heart toxicities induced by CDDP alone or CDDP plus 6MP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据